← Back to Patent Explorer
US5073627A Expired / Lapsed US ⏱️ 0.0 years remaining

Fusion proteins comprising GM-CSF and IL-3

Assignee: Immunex Corp
•
Filing: 1990-08-14
•
Granted: 1991-12-17
•
Expires: 2010-08-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A fusion protein is disclosed which comprises GM-CSF and IL-3. Such fusion proteins more biologically active than GM-CSF or IL-3 alone or GM-CSF and IL-3 combined.

Inventors

  • 👤 Benson M. Curtis
  • 👤 Linda S. Park
  • 👤 David J. Cosman

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 04:32
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/5403; C07K14/53; C07K14/535; C07K19/00; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/036; C07K2319/70; C07K2319/74; C07K2319/75; Y; Y10; Y10S; Y10S530/00; Y10S530/808

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 35 words
A fusion protein having a formula selected from the group consisting of R.sub.1 --R.sub.2,R.sub.2 --R.sub.1,R.sub.1 --L--R.sub.2 and R.sub.2 --L--R.sub.1 wherein R 1 is GM-CSF; R 2 is IL-3; and L is a linker peptide sequence.
Claim 2
Dependent Claim 35 words
A fusion protein having a formula selected from the group consisting of R.sub.1 --R.sub.2,R.sub.2 --R.sub.1,R.sub.1 --L--R.sub.2 and R.sub.2 --L--R.sub.1 wherein R 1 is GM-CSF; R 2 is IL-3; and L is a linker peptide sequence.
Claim 3
Dependent Claim 26 words
A fusion protein according to claim 1, wherein said linker sequence comprises amino acids selected from the group consisting of Gly, Asn, Ser, Thr and Ala.
Claim 4
Dependent Claim 20 words
A fusion protein according to claim 2, wherein the length of said linker sequence is 5 to 15 amino acids.
Claim 5
Dependent Claim 30 words
A fusion protein according to claim 3 selected from the group consisting of amino acid residues 1-271 depicted in FIG. 1 and amino acid residues 1-275 depicted in FIG. 2.
Claim 6
Dependent Claim 29 words
A fusion protein according to claim 3, wherein the fusion protein is huGM-CSF[Leu 23 Asp 27 Glu 39 ](Gly) 4 Ser(Gly) 5 Ser/huIL-3[Pro 8 Asp 15 Asp 70 ].
Claim 7
Dependent Claim 91 words
A fusion protein according to claim 1, wherein the human GM-CSF is selected from the group consisting of huGM-CSF, huGM-CSF[Leu 23 Asp 27 Glu 39 ], huGM-CSF[Leu 23 ], huGM-CSF[Leu 23 Asp 27 ], huGM-CSF[Glu 39 ], huGM-CSF[Asp 27 Glu 39 ], huGM-CSF[Leu 23 Glu 39 ] and huGM-CSF[Asp 27 ] and human IL-3 is selected from the group consisting of huIL-3, huIL-3[Pro 8 Asp 15 Asp 70 ], huIL-3[Asp 70 ], huIL-3[Asp 15 Asp 70 ], huIL-3[Pro 8 Asp 15 ], huIL-3[Pro 8 Asp 70 ], and huIL-3[Asp 15 ].
Claim 8
Dependent Claim 8 words
A fusion protein comprising GM-CSF fused to IL-3.
Claim 9
Dependent Claim 8 words
A fusion protein comprising GM-CSF fused to IL-3.
Claim 10
Dependent Claim 20 words
A composition comprising an effective amount of a fusion protein according to claim 1, and a suitable diluent or carrier.

References Cited (Backward Citations)

WO1985002863A1 Cited
US4935233A Cited
US5032395A Cited
EP0276846A2 Cited
EP0282185A1 Cited
EP0288809A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-12-16 1995-06-17 1995-12-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-12-16 1999-06-17 1999-12-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-12-16 2003-06-17 2003-12-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag